SG11202007200YA - Epilepsy treatment agent - Google Patents
Epilepsy treatment agentInfo
- Publication number
- SG11202007200YA SG11202007200YA SG11202007200YA SG11202007200YA SG11202007200YA SG 11202007200Y A SG11202007200Y A SG 11202007200YA SG 11202007200Y A SG11202007200Y A SG 11202007200YA SG 11202007200Y A SG11202007200Y A SG 11202007200YA SG 11202007200Y A SG11202007200Y A SG 11202007200YA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment agent
- epilepsy treatment
- epilepsy
- agent
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018052974 | 2018-03-20 | ||
| PCT/JP2019/011184 WO2019181854A1 (en) | 2018-03-20 | 2019-03-18 | Epilepsy treatment agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202007200YA true SG11202007200YA (en) | 2020-08-28 |
Family
ID=67986497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202007200YA SG11202007200YA (en) | 2018-03-20 | 2019-03-18 | Epilepsy treatment agent |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11660275B2 (en) |
| EP (1) | EP3769759B1 (en) |
| JP (1) | JP7265526B2 (en) |
| KR (1) | KR20200132858A (en) |
| CN (1) | CN111801096B (en) |
| AU (1) | AU2019239394A1 (en) |
| BR (1) | BR112020017835A2 (en) |
| CA (1) | CA3092295A1 (en) |
| IL (1) | IL276966A (en) |
| MX (1) | MX2020009100A (en) |
| RU (1) | RU2020128731A (en) |
| SG (1) | SG11202007200YA (en) |
| WO (1) | WO2019181854A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024026905A (en) * | 2020-11-25 | 2024-02-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Therapeutic agent for epilepsy |
| WO2023210617A1 (en) * | 2022-04-27 | 2023-11-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Pharmaceutical composition for treatment of parkinson's disease |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3383414A (en) | 1964-08-26 | 1968-05-14 | Sandoz Ag | Benzocycloalkyl sulfamides |
| US3709677A (en) | 1969-06-25 | 1973-01-09 | Sandoz Ag | N-substituted sulfamoyl compounds useful as herbicides |
| DE3623944A1 (en) | 1986-07-16 | 1988-02-11 | Thomae Gmbh Dr K | NEW BENZOLSULFONAMIDO INDANYL COMPOUNDS, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF |
| EP1401805A1 (en) | 2001-06-26 | 2004-03-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Valproyltaurinamide derivatives as anticonvulsant and cns active agents |
| TW200307539A (en) | 2002-02-01 | 2003-12-16 | Bristol Myers Squibb Co | Cycloalkyl inhibitors of potassium channel function |
| DE10332473A1 (en) * | 2003-07-16 | 2005-02-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ambroxol for the treatment of epilepsy |
| MY148809A (en) | 2004-07-06 | 2013-05-31 | Eisai R&D Man Co Ltd | Crystals of 1,2-dihydropyridine compound and their production process |
| MX2007002309A (en) | 2004-08-24 | 2007-10-08 | Johnson & Johnson | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents. |
| US20070155823A1 (en) | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents |
| CN100572365C (en) | 2006-01-26 | 2009-12-23 | 全哲山 | As 1,2 of antiepileptic drug, 4-triazolo [4,3-a] quinoline-1-ketone derivatives and pharmacologically acceptable salt thereof |
| TW200812574A (en) | 2006-05-19 | 2008-03-16 | Janssen Pharmaceutica Nv | Co-therapy for the treatment of epilepsy and related disorders |
| EP2026790A2 (en) | 2006-05-19 | 2009-02-25 | Janssen Pharmaceutica, N.V. | Co-therapy for the treatment of epilepsy and related disorders |
| AR070949A1 (en) | 2007-10-19 | 2010-05-19 | Solvay Pharm Gmbh | COMPOUNDS DERIVED FROM SULFAMATE FOR MEDICAL USE, MEDICINES AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, PROCEDURES TO PREPARE THESE COMPOUNDS AND THEIR USE |
| TW201012803A (en) | 2008-06-06 | 2010-04-01 | Organon Nv | Heterocyclic derivatives |
| CA2758105A1 (en) | 2009-04-09 | 2010-10-14 | N.V. Organon | Indane derivatives |
| ES2858337T3 (en) | 2009-11-13 | 2021-09-30 | Receptos Llc | Selective Sphingosine 1 Phosphate Receptor Modulators and Chiral Synthesis Methods |
| NZ599914A (en) | 2009-11-13 | 2014-08-29 | Receptos Inc | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| US20120302546A1 (en) | 2010-02-04 | 2012-11-29 | Fox Chase Chemical Diversity Center, Inc. | Novel sulfamides exhibiting neuroprotective action and methods for use thereof |
| US20120077814A1 (en) | 2010-09-10 | 2012-03-29 | Zhong Wang | Sulfonamide, sulfamate, and sulfamothioate derivatives |
| WO2012137982A2 (en) * | 2011-04-05 | 2012-10-11 | Takeda Pharmaceutical Company Limited | Sulfonamide derivative and use thereof |
| MY169073A (en) * | 2012-06-21 | 2019-02-13 | Eisai R&D Man Co Ltd | Indanesulfamide derivative |
| AU2014367781B2 (en) | 2013-12-19 | 2019-07-04 | Eisai R&D Management Co., Ltd. | Therapeutic and/or preventive agent comprising 1-indansulfamide derivative for pain |
| KR102283895B1 (en) * | 2013-12-23 | 2021-07-30 | 노파르티스 아게 | Pharmaceutical combinations |
| CA3002930A1 (en) | 2015-11-13 | 2017-05-18 | Eisai R&D Management Co., Ltd. | Pyranodipyridine compound |
-
2019
- 2019-03-18 AU AU2019239394A patent/AU2019239394A1/en not_active Abandoned
- 2019-03-18 CA CA3092295A patent/CA3092295A1/en active Pending
- 2019-03-18 MX MX2020009100A patent/MX2020009100A/en unknown
- 2019-03-18 WO PCT/JP2019/011184 patent/WO2019181854A1/en unknown
- 2019-03-18 JP JP2020507787A patent/JP7265526B2/en active Active
- 2019-03-18 US US16/975,865 patent/US11660275B2/en active Active
- 2019-03-18 RU RU2020128731A patent/RU2020128731A/en unknown
- 2019-03-18 EP EP19772593.0A patent/EP3769759B1/en active Active
- 2019-03-18 KR KR1020207025052A patent/KR20200132858A/en not_active Application Discontinuation
- 2019-03-18 BR BR112020017835-7A patent/BR112020017835A2/en not_active Application Discontinuation
- 2019-03-18 CN CN201980016269.XA patent/CN111801096B/en active Active
- 2019-03-18 SG SG11202007200YA patent/SG11202007200YA/en unknown
-
2020
- 2020-08-26 IL IL276966A patent/IL276966A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020128731A3 (en) | 2022-04-20 |
| US11660275B2 (en) | 2023-05-30 |
| BR112020017835A2 (en) | 2020-12-29 |
| KR20200132858A (en) | 2020-11-25 |
| IL276966A (en) | 2020-10-29 |
| CN111801096B (en) | 2024-03-05 |
| JPWO2019181854A1 (en) | 2021-03-11 |
| EP3769759A1 (en) | 2021-01-27 |
| WO2019181854A1 (en) | 2019-09-26 |
| CN111801096A (en) | 2020-10-20 |
| EP3769759B1 (en) | 2023-11-15 |
| US20210000771A1 (en) | 2021-01-07 |
| EP3769759A4 (en) | 2021-11-17 |
| JP7265526B2 (en) | 2023-04-26 |
| CA3092295A1 (en) | 2019-09-26 |
| MX2020009100A (en) | 2020-12-03 |
| RU2020128731A (en) | 2022-04-20 |
| AU2019239394A1 (en) | 2020-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL269371A (en) | Treatment methods | |
| GB201813876D0 (en) | Treatment | |
| HK1252996A1 (en) | Methods for the treatment of epilepsy | |
| HK1255224A1 (en) | Wound treatment agent | |
| HUE056213T2 (en) | Treatment system | |
| IL288937A (en) | Improved treatment using eyp001 | |
| GB201800546D0 (en) | Treatment | |
| GB201913756D0 (en) | Contrast agent | |
| IL276966A (en) | Epilepsy treatment agent | |
| IL281839A (en) | Treatment methods | |
| IL281792A (en) | Treatment methods | |
| GB201713760D0 (en) | Treatment of epilepsy | |
| GB201914296D0 (en) | Treatment | |
| SI3307267T1 (en) | Multiple sclerosis treatment | |
| SG11202101196TA (en) | Behavioural treatment | |
| GB201912760D0 (en) | Treatment | |
| GB201912365D0 (en) | Treatment | |
| GB201912335D0 (en) | Treatment | |
| GB201911816D0 (en) | Treatment | |
| GB201911603D0 (en) | Treatment | |
| GB201910755D0 (en) | Treatment | |
| GB201814905D0 (en) | Treatment | |
| GB201904253D0 (en) | Treatment | |
| GB201902579D0 (en) | Treatment | |
| GB201902580D0 (en) | Treatment |